Predictive Nomograms for Assessing Axillary Lymph Node Metastasis in Patients with Breast Cancer
By
Zixi Deng
Yuechong Li
Yongchao Luo
Xi Cao
Songjie Shen
November 26, 2025
Clinical Scorecard: Predictive Nomograms for Assessing Axillary Lymph Node Metastasis in Patients with Breast Cancer
At a Glance
Category Detail
Condition Axillary Lymph Node Metastasis in Breast Cancer Key Mechanisms Assessment of lymph node involvement using ultrasound and PET/CT imaging. Target Population Female patients with invasive breast cancer, clinically node-negative (cN0). Care Setting Breast cancer surgical and oncology departments.
Key Highlights
Axillary lymph node status is crucial for treatment decisions in breast cancer. Sentinel Lymph Node Biopsy (SLNB) can replace Axillary Lymph Node Dissection (ALND) in certain cases. Preoperative ultrasound and PET/CT are essential tools for assessing nodal tumor burden. Guideline-Based Recommendations
Diagnosis
Utilize preoperative axillary ultrasound and PET/CT for assessing lymph node status. Management
Consider SLNB for patients with T1 or T2 invasive breast cancer and one or two positive sentinel lymph nodes. Monitoring & Follow-up
Regularly assess lymph node status and treatment response using imaging techniques. Risks
Be aware of complications from SLNB, including wound infection, seroma, and lymphedema. Patient & Prescribing Data
Women diagnosed with early-stage invasive breast cancer.
Accurate preoperative prediction of ALN involvement can guide treatment planning.
Clinical Best Practices
Incorporate imaging findings into clinical decision-making for breast cancer treatment. Use predictive models to assess the risk of axillary lymph node metastasis. References
